Third, the study included participants with class II/III obesity, many of whom had been treated with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and/or mineralocorticoid receptor blockers, which may have affected steroid metabolism. Here, NR3C2 is linked to obesity due to melanocortin 4 receptor deficiency.